Related Experiment Video
Updated: Sep 10, 2025
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Integrating and Simplifying Evidence to Optimize Cardiorenal Guideline-Directed Therapies
Harleen Singh1, Carrie Puckett2, Yennie Q Lucas3
1School of Pharmacy, The University of Texas at El Paso, 500 W. University Avenue, El Paso, TX 79968, USA.
Insights
Early detection and optimized cardiorenal therapy are crucial for slowing chronic kidney disease (CKD) progression. New medications show promise in managing CKD and its cardiovascular complications.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Chronic kidney disease (CKD) is a growing global health concern with high rates of undiagnosed cases.
- CKD significantly increases the risk of cardiovascular disease (CVD) complications, which are the leading cause of mortality in affected individuals.
- The cardiorenal syndrome highlights the intricate link between heart and kidney health, where each condition exacerbates the other.
Purpose of the Study:
- To review evidence on early detection strategies for chronic kidney disease.
- To explore real-world opportunities for slowing CKD progression through optimized cardiorenal therapy.
- To emphasize the importance of managing shared risk factors like hypertension and diabetes.
Main Methods:
- Literature review of current evidence on CKD detection and management.
- Analysis of guideline-directed medical therapy for cardiorenal conditions.
- Evaluation of emerging pharmacological treatments for CKD.
Main Results:
- Emerging medications, including SGLT2 inhibitors and MRAs, demonstrate superior efficacy in slowing CKD progression compared to traditional therapies.
- Optimizing cardiorenal guideline-directed medical therapy can significantly impact patient outcomes.
- Early detection and timely intervention are critical for improving prognosis in CKD patients.
Conclusions:
- Integrated management of cardiorenal conditions is essential for reducing mortality.
- Novel therapeutic agents offer new hope for slowing the progression of chronic kidney disease.
- Addressing undiagnosed CKD and improving access to care, especially in low-resource settings, remains a priority.
Abstract:
Chronic kidney disease (CKD) prevalence is rising worldwide and is projected to become the fifth leading cause of death globally by 2040. The high proportion of undiagnosed early-staged CKD and delayed diagnosis is of significant concern. The access to diagnosis and treatment is also limited in low-resource settings. The majority of individuals with kidney disease succumb to cardiovascular disease complications. Furthermore, heart failure and CKD are closely interconnected, with each condition significantly increasing the risk of developing the other. They share common risk factors, such as high blood pressure and diabetes, and their coexistence worsens prognosis and raises mortality rates. The bidirectional relationship between the heart and kidneys becomes even more complex and challenging in the context of cardiorenal syndrome. Emerging medications, such as sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists, have shown remarkable efficacy in slowing the progression of kidney disease, surpassing the benefits of traditional treatments. This article summarizes the evidence on the early detection of CKD and real-world opportunities to slow the progression of CKD by optimizing cardiorenal guideline-directed medical therapy.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:28Chronic Kidney Disease III: Interprofessional Care
01:30Heart Failure V: Medical Management
01:18Chronic Kidney Disease IV: Nursing Management
01:22Heart Failure Drugs: Diuretics
01:20Acute Kidney Injury V: Interprofessional Care